| 摘要 |
<p>A method of estimating a risk of the expression of a side effect caused by the administration of irinotecan; and a method of relieving the side effect caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter domain of UGT1A1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of a side effect caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the side effect, thereby relieving the side effect caused by the administration of irinotecan.</p> |
